Testosterone Cypionate Plateau & Non-Response Troubleshooting

Is a testosterone cypionate plateau a real thing?

Plateau is not a term used in the prescribing information. It describes one experience: fatigue, low libido or flat mood returning while the testosterone level on the lab report still reads in range.

What can be measured is a short list of things that change what a fixed dose does: where in the injection interval the blood was drawn, how much hormone is unbound, and whether hematocrit or blood pressure has moved since the last check.

Was the blood drawn at the right point in the interval?

The Depo-Testosterone label gives 50 to 400 mg every 2 to 4 weeks, deep into the gluteal muscle, never intravenously [1]. The same label gives the half-life of intramuscular testosterone cypionate as about 8 days [1]. With a dosing interval measured in weeks, a level drawn soon after an injection and a level drawn just before the next one are different measurements of the same regimen. Recording where each draw falls in the interval lets results be compared at a consistent point from visit to visit.

The label also requires the diagnosis to be confirmed before treatment, with morning serum testosterone measured on at least two separate days and both values below the normal range [1].

For cypionate, the label says the dosage is adjusted according to the patient's response and the appearance of adverse reactions [1].

Total testosterone can look adequate while free testosterone is not

The label's pharmacokinetic section states that about 98% of testosterone in plasma is bound to a specific testosterone-estradiol binding globulin and about 2% is free. It says the amount of sex hormone-binding globulin (SHBG) in plasma determines the distribution of testosterone between free and bound forms, and that the free testosterone concentration determines its half-life [1].

Because the label ties the bound/free split to the amount of SHBG, the same total testosterone can correspond to different amounts of unbound hormone in different men.

Hematocrit

The Depo-Testosterone label calls for periodic hemoglobin and hematocrit checks in long-term use [1]. The Xyosted label (a weekly subcutaneous enanthate product) describes checking about every 3 months, stopping when hematocrit becomes elevated until it falls, and stopping permanently if it rises again after restarting; the Azmiro (cypionate) label gives the same stop, restart, stop-permanently rule. The Depo-Testosterone label gives no such hold threshold.

How large the effect is with injections: a network meta-analysis of 29 placebo-controlled trials in 3,393 men found intramuscular testosterone enanthate/cypionate raised mean hematocrit 4.0% versus placebo (95% CI 2.9 to 5.1) [2]. A retrospective single-center review of 178 hypogonadal men followed for 3 years reported erythrocytosis (hematocrit above 50%) in 66.7% of men on injectable testosterone, 12.8% on gels and 35.1% on pellets; the injection group was younger (mean 42.5 vs about 54 years) with higher baseline hematocrit, and the review was not randomized [3]. A separate review put the risk of erythrocytosis (hematocrit above 0.52) at 315% higher than controls and noted that the link between erythrocytosis and clot events remains inconclusive [4].

The Depo-Testosterone label also lists venous thromboembolism among reported events and says to discontinue treatment and begin an appropriate workup if one is suspected [1].

Blood pressure

The Depo-Testosterone label states that testosterone can increase blood pressure, which can increase cardiovascular risk over time, that blood pressure should be monitored periodically, especially in men with hypertension, and that testosterone products are not recommended in uncontrolled hypertension [1]. FDA's 2025 class-wide labeling action required a blood pressure warning for products that lacked one, and the ambulatory blood pressure studies confirmed an increase across all testosterone products [5].

Estradiol

Testosterone is converted to estradiol by the enzyme aromatase, and estrogens have measurable roles in male physiology [6]. Gynecomastia is the estradiol-linked effect the cypionate label names: it may develop and occasionally persists during treatment for hypogonadism [1]. The gynecomastia literature describes an imbalance, with estrogens stimulating breast tissue growth and androgens inhibiting it, and most cases coming from deficient androgen action or excessive estrogen action [7].

What a trial in older men showed

A trial in 790 men aged 65 or older with low testosterone tested testosterone gel, not cypionate, for one year. It found improvements in sexual function and slightly better mood, but no significant benefit on its vitality measure [8]. Raising testosterone from low to mid-normal moved some outcomes and not others, so which symptom stopped responding matters as much as the number.

Other conditions that produce the same symptoms

Sleep apnea: the Azmiro and Xyosted labels warn that testosterone may worsen sleep apnea, and the Endocrine Society guideline recommends against starting testosterone therapy in men with untreated severe sleep apnea [9].

Thyroid: the label states that testosterone may lower thyroxine-binding globulin, reducing total T4 and raising T3/T4 resin uptake, while free thyroid hormone levels stay unchanged and there is no clinical evidence of thyroid dysfunction from this effect [1]. A low total T4 on treatment is not by itself a thyroid diagnosis.

Does raising the dose fix it?

The label's suggested replacement range tops out at 400 mg every 2 to 4 weeks, with the dose adjusted by response and adverse reactions [1]. Intramuscular enanthate/cypionate raised mean hematocrit 4.0% over placebo in the meta-analysis [2], and the label calls for periodic hematocrit and blood pressure monitoring [1]. The large cardiovascular outcome trial, TRAVERSE, enrolled 5,246 men and tested daily 1.62% testosterone gel, not injections; no outcome trial of that size exists for injectable testosterone [11].

Contraindications and interactions in the label

The Depo-Testosterone label lists contraindications that include known or suspected prostate cancer, breast cancer in men, pregnancy, hypersensitivity, and serious cardiac, hepatic or renal disease [1]. It says androgens may increase sensitivity to oral anticoagulants and that the anticoagulant dose may need to be reduced [1]. It also says androgens may lower blood glucose and insulin requirements [1].